| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 3464 | 2016 |
| Clonal heterogeneity and tumor evolution: past, present, and the future N McGranahan, C Swanton Cell 168 (4), 613-628, 2017 | 3102 | 2017 |
| The causes and consequences of genetic heterogeneity in cancer evolution RA Burrell, N McGranahan, J Bartek, C Swanton Nature 501 (7467), 338-345, 2013 | 2842 | 2013 |
| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2622 | 2017 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 2177 | 2017 |
| Chromosomal instability drives metastasis through a cytosolic DNA response SF Bakhoum, B Ngo, AM Laughney, JA Cavallo, CJ Murphy, P Ly, P Shah, ... Nature 553 (7689), 467-472, 2018 | 1656 | 2018 |
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ... Nature genetics 46 (3), 225-233, 2014 | 1471 | 2014 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1462 | 2017 |
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution EC De Bruin, N McGranahan, R Mitter, M Salm, DC Wedge, L Yates, ... Science 346 (6206), 251-256, 2014 | 1368 | 2014 |
| Biological and therapeutic impact of intratumor heterogeneity in cancer evolution N McGranahan, C Swanton Cancer cell 27 (1), 15-26, 2015 | 1330 | 2015 |
| DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution R Rosenthal, N McGranahan, J Herrero, BS Taylor, C Swanton Genome biology 17 (1), 31, 2016 | 1207 | 2016 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 1114 | 2018 |
| Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021, 2017 | 1044 | 2017 |
| Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019 | 940 | 2019 |
| Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition K Litchfield, JL Reading, C Puttick, K Thakkar, C Abbosh, R Bentham, ... Cell 184 (3), 596-614. e14, 2021 | 878 | 2021 |
| Clonal status of actionable driver events and the timing of mutational processes in cancer evolution N McGranahan, F Favero, EC De Bruin, NJ Birkbak, Z Szallasi, ... Science translational medicine 7 (283), 283ra54-283ra54, 2015 | 780 | 2015 |
| Lung adenocarcinoma promotion by air pollutants W Hill, EL Lim, CE Weeden, C Lee, M Augustine, K Chen, FC Kuan, ... Nature 616 (7955), 159-167, 2023 | 719 | 2023 |
| Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ... Cell 173 (3), 595-610. e11, 2018 | 707 | 2018 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 679 | 2018 |
| Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ... Cell 173 (3), 611-623. e17, 2018 | 582 | 2018 |
